Gainers
- Minerva Surgical UTRS stock increased by 22.6% to $0.58 during Friday's after-market session. Trading volume for this security closed at 1.9 million, accounting for 118.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $17.5 million.
- Tenaya Therapeutics TNYA stock moved upwards by 7.97% to $2.98. The market value of their outstanding shares is at $190.6 million.
- Nemaura Medical NMRD stock increased by 7.2% to $1.34. The market value of their outstanding shares is at $38.7 million.
- Nymox Pharmaceutical NYMX stock rose 6.22% to $0.48. The company's market cap stands at $43.2 million.
- SenesTech SNES stock moved upwards by 5.67% to $2.42. The market value of their outstanding shares is at $1.6 million.
- Akebia Therapeutics AKBA shares increased by 4.99% to $0.84. Akebia Therapeutics's trading volume hit 149.2K shares by close, accounting for 7.5% of its average volume over the last 100 days. The company's market cap stands at $155.0 million.
Losers
- Dyadic International DYAI stock fell 9.4% to $1.45 during Friday's after-market session. The company's market cap stands at $41.4 million.
- Vallon Pharmaceuticals VLON stock declined by 7.03% to $0.43. At the close, Vallon Pharmaceuticals's trading volume reached 2.9 million shares. This is 118.7% of its average volume over the last 100 days. The company's market cap stands at $5.7 million.
- Calyxt CLXT stock decreased by 6.01% to $0.34. The company's market cap stands at $16.4 million.
- OncoCyte OCX stock fell 5.81% to $0.37. The company's market cap stands at $43.8 million.
- NeuBase Therapeutics NBSE stock fell 5.46% to $0.31. The market value of their outstanding shares is at $10.3 million.
- Adamis Pharmaceuticals ADMP stock declined by 5.39% to $0.25. The market value of their outstanding shares is at $36.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in